Advances have been made in drug formulation and schedules of chemotherapy to better the safety profile and efficacy of doxorubicin.
Although mTOR inhibitors share the same mechanism of action, differences in metabolism, formulation and dosing schedule underpin distinct PK/PD profiles such that they may be differentiated for use in a variety of treatment niches.
More recently, the exciting results observed with the combination of vinorelbine and trastuzumab in patients with Her-2 overexpressing/amplified tumours, as well as the development of a reliable formulation and revised schedule of oral vinorelbine with proven activity in ABC appear to have revived the interest in this compound in the management of this disease.
Although receipt of benzodiazepines and the benzodiazepine dose were associated with increased risk of death from overdose, the formulation and dosing schedule were found to be largely unrelated after adjustment for potential confounders.
We first provide a mixed-integer linear programming (MILP) formulation for assigning and scheduling independent tasks with reliability and temperature constraints on the heterogeneous platform to minimize the makespan.
Although the FAEs formulation and the dosage schedule are different than those used in the treatment of psoriasis, the safety profile of this FAE formulation seems similar to that of FAE treatment in psoriasis.
These data help provide a foundation for future studies aimed at optimizing synbiotic formulations and treatment schedules in HIV patients.
As different formulations and dosing schedules are likely to have economic implications, we aimed to evaluate their efficacy, safety, and costs in nine European countries: Austria, Belgium, Czech Republic, Hungary, Italy, Latvia, Netherlands, Poland, and Portugal.
Efforts to further improve the formulation and optimize dose and schedule of vaccination are being continued in a second clinical trial evaluating lower vaccine doses, and a variation in the intervals between vaccination [35].
A previous study in children and adolescents has demonstrated equivalence between a two-dose primary vaccination schedule of the Adult formulation and a three-dose schedule of the Paediatric formulation of this vaccine in terms of seroprotection against hepatitis B infection [ 8, 11, 12].
